Glaucoma patients more likely to suffer from hysteria

Article

Patients with open angle glaucoma (OAG) are more likely to have abnormal Minnesota Multiphasic Personality Inventory-2 (MMPI-2) scores in the areas that focus upon concerns of somatic complaints and poor health.

Patients with open angle glaucoma (OAG) are more likely to have abnormal Minnesota Multiphasic Personality Inventory-2 (MMPI-2) scores in the areas that focus upon concerns of somatic complaints and poor health, according to a study published in the December 2007 issue of the Journal of Glaucoma.

Michele Lim from the University of California, Davis, Sacramento, California, USA and colleagues conducted a study to characterize the personality profile of glaucoma subjects. A total of 108 subjects, 56 with OAG and 52 controls, were given the MMPI-2 test, in addition to performing automated perimetry.

Subjects with OAG had significantly higher hypochondriasis, hysteria and health concern scores than the control subjects. OAG subjects also had a significantly greater frequency of clinically abnormal scores for hysteresis and health concerns. Multivariate analysis of variance revealed that hypochondriasis, hysteria and health concerns scores were related to the number of systemic medications used.

The researchers believe that the use of systemic medications may be a constant reminder of illness, perhaps explaining the higher MMPI-2 scores in patients with OAG.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.